AIRS — AirSculpt Technologies, Inc.

Summary of AirSculpt Technologies, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $33.4 million, down 15% year-over-year; same-store revenue declined 16%.
• Adjusted EBITDA: $2.5 million (7.4% margin), an increase of $0.6 million and 2.8% margin expansion compared to Q4 2024.
• Full Year Revenue: $151.8 million, a decrease of 15.8% from fiscal 2024.
• Full Year Adjusted EBITDA: Approximately $15 million (10% margin), down from $21 million (12% margin) in fiscal 2024.
• Debt Management: Paid down $19 million in debt during 2025; gross debt outstanding at year-end was $56 million, with a leverage ratio below 3x.

2. Strategic Updates and Business Highlights

• Operational Improvements: The company focused on rebuilding and transforming operations, leading to stabilization and positive same-store sales growth starting February 2026.
• New Services: Introduced skin tightening and skin removal procedures, with over 100 skin removal surgeries completed in Q4 2025. These services are expected to enhance revenue streams.
• Marketing Strategy: Implemented an enhanced marketing strategy that includes new mediums and improved patient financing options, contributing to improved volume trends.
• Leadership Changes: New executives were added to strengthen the management team, particularly in finance, legal, and operations.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be in the range of $151 million to $157 million, reflecting approximately 3% comparable growth.
• Adjusted EBITDA Guidance: Projected between $15 million and $17 million for fiscal 2026, benefiting from improved revenue growth and cost savings.
• Focus on Existing Centers: No new center openings planned for 2026 as resources will be directed towards enhancing revenue growth in existing locations.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Continued decline in revenue and same-store sales for Q4 2025, reflecting a challenging consumer spending environment.
• Delayed 10-K Filing: Issues related to intercompany transactions and lease accounting led to a delay in the 10-K filing, although it did not impact cash or operations.
• Market Risks: The company is monitoring supply chain issues related to helium plasma for skin tightening procedures, which could affect service delivery.

5. Notable Q&A Insights

• Seasonality of Revenue: Management acknowledged that while Q1 2026 revenue is expected to decline slightly year-over-year, they are confident in the full-year outlook due to improving trends.
• Core Business Stability: The core body contouring business is stabilizing, with expectations that GLP-1-related procedures will drive future growth.
• Customer Feedback on New Procedures: Early feedback on skin removal procedures has been positive, with good results reported by patients and surgeons, indicating potential for broader rollout.
• Capital Allocation Strategy: The focus remains on maintaining a healthy balance sheet, with continued debt paydown prioritized alongside investments in growth initiatives.

This summary encapsulates the key points from the earnings call, highlighting both the positive strides made by AirSculpt and the challenges they face moving forward.